Measurement of cytogenetic endpoints in lymphocytes of children diagnosed with attention deficit/hyperactivity disorder (ADHD) and treated with methylphenidate or adderall [amfetamine mixed salts]

Trial Profile

Measurement of cytogenetic endpoints in lymphocytes of children diagnosed with attention deficit/hyperactivity disorder (ADHD) and treated with methylphenidate or adderall [amfetamine mixed salts]

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Feb 2017

At a glance

  • Drugs Methylphenidate (Primary) ; Mixed amfetamine salts (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Pharmacodynamics; Pharmacogenomic
  • Most Recent Events

    • 01 Dec 2008 Results were published in the Journal of the American Academy of Child and Adolescent Psychiatry.
    • 21 Sep 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 10 Aug 2008 Exclusion criteria ammended as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top